Cancer of the Rectum Clinical Trial
The main objective of this randomized trial is to compare 5FU/LV (Mayo-Clinic regimen or LV5FU2) to LV5FU2 + irinotécan in patients with resected B2 and C rectal cancer. Preoperative radiotherapy is recommended but not mandatory. Main endpoint is disease free survival. Secondary endpoint are overall survival, time to local recurrence, time to distant metastases, and tolerance. A total of 600 patients will be included in the trial.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
| Recruiting |
NCT03573791 -
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
|
||
| Completed |
NCT00308516 -
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
|
Phase 2 | |
| Terminated |
NCT04150705 -
PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
|
N/A | |
| Active, not recruiting |
NCT05179837 -
Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps
|
N/A | |
| Completed |
NCT02017509 -
Immunoscore in Rectal Cancer
|
||
| Active, not recruiting |
NCT01804790 -
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
|
Phase 3 |